Hyaluronic Acid Intra-articular Products Medicare Advantage

Medicare Advantage covers specified hyaluronic acid intra‑articular products (e.g., Hyalgan, Synvisc/Synvisc‑One, Euflexxa, Durolane, Monovisc, Genvisc 850, etc.) only for FDA‑approved treatment of osteoarthritis of the knee and not for other joints or non‑FDA indications. Coverage requires radiologic confirmation of knee OA, documentation of trials of ≥2 non‑pharmacologic modalities and ≥2 pharmacologic therapies, at least two prior intra‑articular corticosteroid injections before initial approval, adherence to product‑specific dosing, approvals are for 6 months, and reauthorization requires prior response and ≥6 months since the last HA injection.

"A hyaluronic acid intra-articular product is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic th..."

Sign up to see full coverage criteria, indications, and limitations.